ArticleThe journal of nutrition, health & aging2026
Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMetabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent metabolic condition closely linked to aging and is associated with an elevated risk of chronic kidney disease (CKD). Sarcopenia, a hallmark of aging, has emerged as a major global health concern; however, its role in the development of CKD among patients with MASLD remains unclear. This study aimed to investigate whether sarcopenia and progressive muscle loss increase CKD risk in patients with MASLD.
methodsThis cohort included 19,867 MASLD adults without baseline CKD. Sarcopenia was defined using the skeletal muscle mass index (SMI), and muscle change was calculated from baseline to follow-up. MASLD severity was assessed using the fibrosis-4 score. CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m².
resultsOver 124,236 person-years (median 5.6 years), 993 participants developed CKD. In patients with MASLD, the adjusted hazard ratio (aHR) for incident CKD in participants with sarcopenia compared to those without was 1.41 (95% CI: 1.12-1.77). Furthermore, gradual muscle loss was associated with a higher CKD risk, demonstrating a dose-dependent relationship. Participants with progressive muscle loss had an aHR of 1.13 (95% CI: 1.00-1.29) for CKD development compared to those with preserved or increased muscle mass. The risk of CKD also increased with MASLD severity.
conclusionSarcopenia and progressive muscle loss were independently associated with CKD development in patients with MASLD, with a greater risk observed among those with advanced fibrosis. Assessment of muscle mass and prevention of muscle decline may help identify aging individuals with MASLD who are at increased risk of CKD and potentially delay its onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.